J Korean Med Sci.  1995 Aug;10(4):258-262. 10.3346/jkms.1995.10.4.258.

Analysis of nm23 expression as a prognostic parameter in renal cell carcinoma

Affiliations
  • 1Department of Urology, Yonsei University College of Medicine, Seoul, Korea.
  • 2Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.

Abstract

To identify the clinicopathological events including nm23 expression that underlies progression in renal cell carcinoma, a retrospective analysis of patients with renal cell carcinoma was performed. Ninety-eight cases of radical nephrectomies with extensive regional or para-aortic lymph node dissection were assessed for clinicopathological variables, and eighty-five cases underwent nm23/NDPK-A protein immunohistochemical staining. Significant parameters in survival were tumor size, histologic pattern, Fuhrman's nuclear grade, pathologic T(pT) stage, pathologic N stage, M stage, tumor thrombi, location of metastasis, and nm23 staining intensity. To assess the relationship with survival, the tumors with low and high nm23 expressions were compared. The fifty-nine patients with a high staining intensity had a significantly worse survival than did the twenty-six with a low staining intensity (p = 0.0015). Additionally nm23 staining intensity was correlated with tumor size, Fuhrman's nuclear grade, pT, and distant metastasis. Therefore, the immunostaining intensity of nm23 protein could be used as a prognostic parameter with an inverse correlation.

Keyword

Renal cell carcinoma; nm23; Immunohistochemistry; Prognostic parameter

MeSH Terms

Adult
Aged
Carcinoma, Renal Cell/*enzymology/mortality/pathology
Disease-Free Survival
Female
Human
Kidney Neoplasms/*enzymology/mortality/pathology
Male
Middle Age
Neoplasm Staging
Nucleoside-Diphosphate Kinase/*analysis
Prognosis
Transcription Factors/*analysis
Full Text Links
  • JKMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr